Welcome to 4SC

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Information about Capital increase June/July 2015 (completed)

13 Aug 2015
4SC AG / Key word(s): Patent 2015-08-13 / 07:30 Press Release 4SC strengthens patent protection for its epigenetic cancer drug candidate 4SC-202 in growth market China...
4SC-202: positive Phase I data ASCO 2014

Epigenetic compound 4SC-202 shows clean safety and promising signs of efficacy in haematological tumours press release, ASCO 2014 poster

Resminostat: Advancing Phase II

4SC: Phase II trial in haematological cancer indication CTCL planned... more
Yakult: Japanese Phase II trials in HCC & NSCLC ongoing ...

Learn more about 4SC

Sign up to receive press releases and financial reports... more